Detection of anti-Hsp60 antibodies in the serum of patients with prostate cancer

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
DOI: https://doi.org/10.30841/2307-5090.2(57).2016.82981

##plugins.themes.bootstrap3.article.main##

В. М. Григоренко
ДУ «Інститут урології НАМН України», м. Київ, Ukraine
Л. Ф. Яковенко
Інститут молекулярної біології та генетики НАН України, м. Київ, Ukraine
М. В. Вікарчук
ДУ «Інститут урології НАМН України», м. Київ, Ukraine
Р. О. Данилець
ДУ «Інститут урології НАМН України», м. Київ, Ukraine
М. О. Косюхно
ДУ «Інститут урології НАМН України», м. Київ, Ukraine
І. В. Крупська
Інститут молекулярної біології та генетики НАН України, м. Київ, Ukraine
Л. Л. Сидорик
Інститут молекулярної біології та генетики НАН України, м. Київ, Ukraine

Abstract

A detection of the level of antibodies to heat shock protein Hsp60 in the serum of 55 prostate cancer patients who performed a radical prostatectomy was done. Donor’s blood serum was used as control (n=67). It’s found that the anti-Hsp60 antibodies level were increased in prostate cancer patient’s serum in comparison with the control samples. No consistent correlation was found between the levels of antiHsp60 antibodies and the clinical and morphological characteristics of the tumor (stage, PSA level, Gleason score). It has been found the tendency to increasing of the anti-Hsp60 antibodies level in the patient serum who had the prostate cancer recurrence.

##plugins.themes.bootstrap3.article.details##

How to Cite
Григоренко, В. М., Яковенко, Л. Ф., Вікарчук, М. В., Данилець, Р. О., Косюхно, М. О., Крупська, І. В., & Сидорик, Л. Л. (2016). Detection of anti-Hsp60 antibodies in the serum of patients with prostate cancer. Health of Man, (2(57), 154–157. https://doi.org/10.30841/2307-5090.2(57).2016.82981
Issue
No. 2(57) (2016)
Section
Oncology
Copyright (c) 2020 В. М. Григоренко, Л. Ф. Яковенко, М. В. Вікарчук, Р. О. Данилець, М. О. Косюхно, І. В. Крупська, Л. Л. Сидорик

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

References

Ferlay J., Soerjomataram I., Ervik M. et al., GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11, International Agency for Research on Cancer, Lyon, France, 2012, http://globocan.iarc.fr/

Ahmadi H. and Daneshmand S. Androgen deprivation therapy for prostate cancer: longterm safety and patient outcomes // Patient Related Outcome Measures. – 2014. – Vol. 5. – P. 63–70.

Katsogiannou M., Ziouziou H., Karaki S. et al. The hallmarks of castrationresistant prostate cancers // Cancer Treatment Reviews. – 2015. – Vol. 41. – 7. – P. 588–597.

Leitzmann M.F. Risk factors for the onset of prostatic cancer: age, location and behavioral correlates / M.F. Leitzmann, S. Rohrmann // Clin. Epidemiol – 2012. – Vol .4. – P. 1–11.

Mullins J.K, Han M., Pierorazio P.M. et al. Radical prostatectomy outcome in men 65 years old or older with low risk prostate cancer // J. Urol. – 2013. – Vol. 187. – P. 1620–5.

Bott SRJ. Management of recurrent disease after radical prostatectomy // Prostate Cancer and Prostatic Diseases. – 2004. – Vol. 7. – P. 211–216.

D’Amico AV, Whittington R, Malkowicz SB. et al. The combination of preoperative prostate specific antigen and postoperative pathological findings to predict prostate specific antigen outcome in clinically localized prostate cancer // J Urol. – 1998. – Vol. 160 (6 pt 1). – P. 2096–2101.

Grossfeld GD, Latini DM, Lubeck DP. et al. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer // J Urol. – 2003. – Vol. 169. – P. 157–63.

Swanson GP, Riggs M, Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death // Urol Oncol. – 2007. – Vol. 25 – P. 110–4.

Cappello F, Czarnecka AM, La Rocca G, Di Stefano A, Zummo G, et al. Hsp60 and Hsp10 as antitumor molecular agents // Cancer Biol. – 2007. – Ther 6. – P. 487–489.

Cappello F., Conway de Macario E., Marasa L. et al. Hsp60 expression, new locations, functions and perspectives for cancer diagnosis and therapy // Cancer Biol Ther. – 2008. – 7. – P. 801–809.

Cappello F, de Macario E, Zummo G, Macario A. Immunohistochemistry of human Hsp60 in health and disease: from autoimmunity to cancer // Methods Mol Biol. – 2011. – 787. – P. 245–54.

Cappello F, Angileri F, de Macario E, Macario A. Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks // Curr Pharm Des. – 2013. – 19 (3). – P. 452–7.

Macario A., Conway de Macario E. Chaperonopathies by defect, excess, or mistake // Ann N Y Acad Sci. – 2007. – 1113. – P. 178–191.

Calderwood S., Mambula S., Gray J., Theriault J. Extracellular heat shock proteins in cell signaling // FEBS Lett. – 2007. – 581. – P. 3689–3694.

Chandra D, Choy G, Tang DG. Cytosolic accumulation of HSP60 during apoptosis with or without apparent mitochondrial release: evidence that its proapoptotic or pro-survival functions involve differential interactions with caspase-3 // J Biol Chem. – 2007. – 282. – P. 31289–31301.

Qian-Lin Z, Ting-Feng W, Qi-Feng C et al. Inhibition of cytosolic chaperonin CCTf-1 expression depletes proliferation of colorectal carcinoma in vitro // J Surg Oncol – 2010. – 102. – P. 419–423.

Dong D, Stapleton C, Luo B et al. A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis // Cancer Res. – 2011. – 71. – P. 2848–2857.

Kimura E, Enns R, Alcaraz J et al. Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60 // J Clin Oncol. – 1993. – 11 (5). – P. 891–8.

Schneider J. et al. Immunohistochemical detection of HSP60expression in human ovarian cancer. Correlation with survival in a series of 247 patients // Anticancer Res. – 2004. – 19. – P. 2141–2146.

Chant I.D., Rose P.E., and Morris A.G. Analysis of heat shock protein expression in myeloid leukaemia cells by flow cytometry // Br. J. Haematol. – 1995 – 90. – P. 163–168.

Franzen B., Linder S., Alaiya A.A. et al. Analysis of polypeptide expression in benign and malignant human breast lesions // Electrophoresis. – 1997. – 18. – P. 582–587.

Kamishima T, Fukuda T, Usuda H et al. Carcinosarcoma of the urinary bladder: expression of epithelial markers and different expression of heat shock proteins between epithelial and sarcomatous elements // Pathol Int. – 1997. – 47 (2–3). – P. 166–73.

Piselli P., Vendetti S, Vismara D, Cicconi R, Poccia F et al. Different expression of CD44, ICAM-1, and HSP60 on primary tumor and metastases of a human pancreatic carcinoma growing in scid mice // Anticancer Res. – 2000. – 20. – P. 825–831.

Kato S, Kato M, Hirano A et al. The immunohistochemical expression of stressresponse protein (srp) 60 in human brain tumours: relationship of srp 60 to the other five srps, proliferating cell nuclear antigen and p53 protein // Histol Histopathol. – 2001. – 16 (3). – P. 809–20.

Cappello F, Bellafiore M, Palma A et al. 60KDa chaperonin (HSP60) is over-expressed during colorectal carcinogenesis // Eur J Histochem. – 2003. – 47 (2). – P. 105–10.

Pignatelli D, Ferreira J, Soares P, Costa M, Magalhges M. Immunohistochemical study of heat shock proteins 27, 60 and 70 in the normal human adrenal and in adrenal tumors with suppressed ACTH production // Microsc Res Tech. – 2003. – 61 (3). – P. 315–23.

Cappello F, Bellafiore M, Palma A, Marciano V, Martorana G et al. Expression of 60-kD heat shock protein increases during carcinogenesis in the uterine exocervix. Pathobiology. – 2002. – 70. – P. 83–88.

Cornford P, Dodson A, Parsons K et al. Heat shock protein expression independently predicts clinical outcome in prostate cancer // Cancer Res. – 2000. – 60 (24). – P. 7099–105.

Cappello F. et al. Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis // Anticancer Res. – 2003. – 23. – P. 1325–1331.

Ya-Ping Tsai, Muh-Hwa Yang, Chi-Hung Huang et al. Interaction between HSP60 and bcatenin promotes metastasis // Carcinogenesis. – 2009. – Vol. 30. – 6. – P. 1049–1057.

Ito T, Kawabe R, Kurasono Y, Hara M, Kitamura H et al. Expression of heat shock proteins in squamous cell carcinoma of the tongue: an immunohistochemical study // J Oral Pathol Med. – 1998. – 27. – P. 18–22.

Lebret T, Watson RW, Molinieg' V, O’Neill A, Gabriel C et al. Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma // Cancer. – 2003. – 98. – P. 970–977.

Cappello F, Di Stefano A, D’Anna SE et al. Immunopositivity of heat shock protein 60 as a biomarker of bronchial carcinogenesis // Lancet Oncol. –2005. – 6. – P. 816.

Hsu PL, Hsu SM. Abundance of heat shock proteins (Hsp89, Hsp60, and Hsp27) in malignant cells of Hodgkin’s disease // Cancer Res. – 1998. – 58. – P. 5507–5513.

Trieb K., Gerth R., Windhager R. et al. Serum antibodies against the Heat shock protein 60 are elevated in patients with osteosarcoma // Immunobiology. – 2000. – Vol. 201. – Issues 3–4. – P. 368–376.

Soltys BJ, Gupta RS Cell surface localization of the 60 kDa heat shock chaperonin protein (hsp60) in mammalian cells // Cell Biol Int. – 1997. – 21. – P. 315–320.

Osterloh A., Meier-Stiegen F., Veit A., Fleisher B., von Bonin A. Lipopolysaccharidefree heat shock protein 60 activates T cells // J.Biol. Chem. – 2004. – 279. – P. 4790647911.

Feng H., Zeng Y., Graner M.W., Katsanis E. Stressed apoptotic tumor cells stimulate dendritic cells and induce specific cytotoxic T cells // Blood. – 2002. – 100. – P. 4108–4115.

Wu T., Tanguay R. Antibodies against heat shock proteins in environmental stresses and diseases:frend or foe? // Cell Stress Chaper. – 2006. – 11, No 1. – P. 1–12.

Bodzek P., Partyka R., DamasiewiczBodzek A. Antibodies against Hsp60 and Hsp65 in the sera of women with ovarian cancer // J Ovarian Res. – 2014. – 7:30. doi: 10.1186/1757-2215-7-30.

Avrames S., Termynck T. Monoclonal IgG and autoantibodies obtained after polyclonal activation, show reactivities similar to those of polyclonal natural autoantibodies // Mol. Immunol. – 1993. – V. 30. – P. 119–127.

Kapustjan L.N., Kijamova R.G., Grishkova V.S., Terent'ev A.G., Filonenko V.V., Sidorik L.L. Poluchenie rekombinantnogo shaperona GroEL i ego immunologicheskaja kross-reaktivnost' s Hsp60 // Biopolym. Cell. – 2006. – 22. – No 2. – P. 117–121.

Vigontina O., Efimenko O., Yakovenko L, Kiyamova R., Filonenko V., Gout I., Ros N., Kosey N., Tatarchuk T., Sidorik L., Matsuka G. Chaperon Hsp60 as autoantigen in development of dyshormonal diseases // Jeksperiment.onkologija. – 2002. – T. 24 (2). – C. 112–115.

Wu C., Chang Y., Chang K., Liu Y., Liu H., Lee I., Yu J., Chiang W. Salivary auto-antibodies as noninvasive diagnostic markers of oral cavity squamous cell carcinoma // Cancer Epidemiol Biomarkers Prev. – 2014. – 23 (8). – P. 1569–78.

Varbiro Sz., Biro A., Cervenak J., Singh M., Banhidy F., Sebestyen A., Fust G., Prohaszka Z. Human anti-60 kD heat shock protein autoantibodies are characterized by basic features of natural autoantibodies // Acta Physiol.Hungar. – 2010. – 97, No 1. – P. 1–10.

Hrbacek J., Urban M., Hamsikova E., Tachezy R., Heracek J. Thirty years of research on infection and prostate cancer: No conclusive evidence for a link. A systematic review // Urologic Oncology: Seminars and Original Investigations – 2013. – 31. – P. 951–965.